Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Net Cash Flow (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Net Cash Flow for 7 consecutive years, with $244.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 2456.02% to $244.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $236.8 million, a 2204.69% increase, with the full-year FY2025 number at $236.8 million, up 2204.69% from a year prior.
  • Net Cash Flow was $244.1 million for Q4 2025 at Kymera Therapeutics, up from -$222.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $245.9 million in Q2 2025 to a low of -$222.9 million in Q3 2025.
  • A 5-year average of $16.5 million and a median of $15.8 million in 2021 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: crashed 1470.87% in 2024, then skyrocketed 2456.02% in 2025.
  • Kymera Therapeutics' Net Cash Flow stood at -$104.3 million in 2021, then grew by 16.36% to -$87.2 million in 2022, then skyrocketed by 133.16% to $28.9 million in 2023, then crashed by 66.99% to $9.5 million in 2024, then surged by 2456.02% to $244.1 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Net Cash Flow are $244.1 million (Q4 2025), -$222.9 million (Q3 2025), and $245.9 million (Q2 2025).